NEW APPROACHER IN THE DEVELOPMENT OF ALZHEIMER’S DISEASE MODIFYING DRUGS

NEW APPROACHER IN THE DEVELOPMENT OF ALZHEIMER’S DISEASE MODIFYING DRUGS

Pedro César de Souza

Mauricio de Nassau University Center. Recife, PE, Brasil

Introduction: Alzheimer’s disease is a more common neurodegenerative disease, affecting 25 million people worldwide, or accounting for about 60 to 70% of all dementia cases. There is currently no exact mechanism to explain the pathophysiology of Alzheimer’s disease, however, cascading metabolic amyloid and post-translational review of tau protein are used as major hypotheses.

Objective: To demonstrate in the literature new approaches in the development of Alzheimer’s disease modifiers. Methodology: This is a literature review study with a 5-year time frame, developed from the research of scientific articles published in international journals, through online databases such as “PubMed” and “Science Direct”.

Results: Alzheimer’s disease-modifying drugs are not yet available, but many patients may, however, develop phase III clinical trials and are intended to modify as pathological stages leading to the disease. As disease-modifying therapies under study, these changes also affect Aβ and tau protein and also cause inflammation and oxidative damage. The results obtained in the clinical trials performed were positive and promising and are still under study. The results show that there is still a long way to go in the development of Alzheimer’s disease modifying drugs.

Conclusion: The results demonstrated that there is still a long way to go in the development of Alzheimer’s disease modifying drugs, but nevertheless levels at the research level should be continued in order to improve the pathophysiology of the disease and find an effective treatment for this disease the same.

Keywords: Alzheimer’s disease, β-amyloid, Tau hyperphosphorylation, Neurodegeneration

Free Full-text PDF

How to cite this article:
Pedro César de Souza. NEW APPROACHER IN THE DEVELOPMENT OF ALZHEIMER’S DISEASE MODIFYING DRUGS. International Journal of Aging Research, 2022, 5:94. DOI: 10.28933/ijoar-2022-01-2005

References:

1. EU Joint Programme – Neurodegenerative Disease. What is neurodegenerative disease?. JPND. 2017
2. Taipa R, Pinho J, Melo-Pires M. Clinico-pathological correlations of the most common neurodegenerative dementias. Front Neurol. 2017 Jan;3: 68.
3. Dalvi A. Alzheimer’s Disease. Dis Mon. 2018 Dec;58(12):666–77.
4. Castellani RJ, Rolston RK, Smith MA. Alzheimer Disease. Dis Mon. 2018 Sep;56(9):484–546.
5. Xiaoting S, Jin L, Ling P. Review of drugs for Alzheimer’s disease. Drug Discov Ther. 2017;6(6):285–90.
6. Mu Y, Gage FH. Adult hippocampal neurogenesis and its role in Alzheimer’s disease. Mol Neurodegener. 2019 Jan;6: 85.
7. Dong S, Duan Y, Hu Y, Zhao Z. Advances in the pathogenesis of Alzheimer’s disease: a re-evaluation of amyloid cascade hypothesis. Transl Neurodegener. BioMed Central Ltd; 2018 Jan 21;1(1):18.
8. Galimberti D, Scarpini E. Disease-modifying treatments for Alzheimer’s disease. Ther Adv Neurol Disord. 2018;4(4):203–16.
9. Chu LW. Alzheimer’s disease: early diagnosis and treatment. Hong Kong Med J. 2018;18(3):228–37.
10. Alzheimer’s Disease International. Relatório sobre a Doença de Alzheimer no Mundo. 2018.
11. Sosa-Ortiz AL, Acosta-Castillo I, Prince MJ. Epidemiology of Dementias and Alzheimer’s Disease. Arch Med Res. Elsevier Inc; 2017;43(8):600–8.
12. Chen JH, Lin KP, Chen YC. Risk Factors for Dementia. J Formos Med Assoc. Formosan Medical Association & Elsevier; 2017;108(10):754–64.
13. World Health Organization. Dementia: a public health priority. World Health Organization. Reino Unido; 2017. Novas abordagens no desenvolvimento de fármacos modificadores da Doença de Alzheimer 64
14. Associação Alzheimer Portugal. Plano Nacional de Intervenção Alzheimer. 2019.
15. Fiţa IG, Enciu A-M, Stănoiu BP. New insights on Alzheimer’s disease diagnostic. Rom J Morphol Embryol. 2020 Jan;52(3 Suppl):975–9.
16. Anderson SH. Alzheimer Disease. Medscape. 2019.
17. Morris JK, Honea RA, Vidoni ED, Swerdlow RH, Burns JM. Is Alzheimer’s disease a systemic disease? Biochim Biophys Acta. 2020 Sep;1842(9):1340–9.
18. Lemere CA. Immunotherapy for Alzheimer’s disease: hoops and hurdles. Mol Neurodegener. Molecular Neurodegeneration; 2020;8(1):36.
19. Perl DP. Neuropathology of Alzheimer’s Disease. Mt Sinai J Med. 2019;77(1):32– 42.
20. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological Alterations in Alzheimer Disease. Cold Spring Harb Perspect Med. 2021;1(1):1– 24.